




PHARMACEUTICAL 2020

Urovant Sciences Ltd.
Rank 224 of 358





PHARMACEUTICAL 2020

Urovant Sciences Ltd.
Rank 224 of 358

The relative strengths and weaknesses of Urovant Sciences Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Urovant Sciences Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 81% points. The greatest weakness of Urovant Sciences Ltd. is the variable Research and Development, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is 28%, being 8.6% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	98,510
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,817
Liabilities, Non-Current	13,534
Other Assets	688
Other Compr. Net Income	262
Other Expenses	304
Other Liabilities	0
Other Net Income	-259
Other Revenues	0
Property and Equipment	923
Research and Development	92,198
Selling, General and Administrative Expense	18,585

Output Variable	Value in 1000 USD
Assets	100,121
Liabilities	25,351
Expenses	111,087
Revenues	0
Stockholders Equity	74,770
Net Income	-111,346
Comprehensive Net Income	-111,215
Economic Capital Ratio	28%